Uterine-Artery Embolization or Myomectomy for Uterine Fibroids
- PMID: 32726530
- DOI: 10.1056/NEJMoa1914735
Uterine-Artery Embolization or Myomectomy for Uterine Fibroids
Abstract
Background: Uterine fibroids, the most common type of tumor among women of reproductive age, are associated with heavy menstrual bleeding, abdominal discomfort, subfertility, and a reduced quality of life. For women who wish to preserve their uterus and who have not had a response to medical treatment, myomectomy and uterine-artery embolization are therapeutic options.
Methods: We conducted a multicenter, randomized, open-label trial to evaluate myomectomy, as compared with uterine-artery embolization, in women who had symptomatic uterine fibroids and did not want to undergo hysterectomy. Procedural options included open abdominal, laparoscopic, or hysteroscopic myomectomy. The primary outcome was fibroid-related quality of life, as assessed by the score on the health-related quality-of-life domain of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire (scores range from 0 to 100, with higher scores indicating a better quality of life) at 2 years; adjustment was made for the baseline score.
Results: A total of 254 women, recruited at 29 hospitals in the United Kingdom, were randomly assigned: 127 to the myomectomy group (of whom 105 underwent myomectomy) and 127 to the uterine-artery embolization group (of whom 98 underwent embolization). Data on the primary outcome were available for 206 women (81%). In the intention-to-treat analysis, the mean (±SD) score on the health-related quality-of-life domain of the UFS-QOL questionnaire at 2 years was 84.6±21.5 in the myomectomy group and 80.0±22.0 in the uterine-artery embolization group (mean adjusted difference with complete case analysis, 8.0 points; 95% confidence interval [CI], 1.8 to 14.1; P = 0.01; mean adjusted difference with missing responses imputed, 6.5 points; 95% CI, 1.1 to 11.9). Perioperative and postoperative complications from all initial procedures, irrespective of adherence to the assigned procedure, occurred in 29% of the women in the myomectomy group and in 24% of the women in the uterine-artery embolization group.
Conclusions: Among women with symptomatic uterine fibroids, those who underwent myomectomy had a better fibroid-related quality of life at 2 years than those who underwent uterine-artery embolization. (Funded by the National Institute for Health Research Health Technology Assessment program; FEMME Current Controlled Trials number, ISRCTN70772394.).
Copyright © 2020 Massachusetts Medical Society.
Comment in
-
Comparing Apples to Apples for Fibroids.N Engl J Med. 2020 Jul 30;383(5):489-490. doi: 10.1056/NEJMe2017266. N Engl J Med. 2020. PMID: 32726537 No abstract available.
-
Myomectomy versus Uterine Artery Embolization: More Alike than Different.J Vasc Interv Radiol. 2020 Nov;31(11):1838-1839. doi: 10.1016/j.jvir.2020.08.023. Epub 2020 Oct 2. J Vasc Interv Radiol. 2020. PMID: 33012651 No abstract available.
-
Uterine-Artery Embolization or Myomectomy for Uterine Fibroids.N Engl J Med. 2020 Nov 26;383(22):2185. doi: 10.1056/NEJMc2028904. N Engl J Med. 2020. PMID: 33252876 Free PMC article. No abstract available.
-
Uterine-Artery Embolization or Myomectomy for Uterine Fibroids.N Engl J Med. 2020 Nov 26;383(22):2185-2186. doi: 10.1056/NEJMc2028904. N Engl J Med. 2020. PMID: 33252877 No abstract available.
-
Uterine-Artery Embolization or Myomectomy for Uterine Fibroids.N Engl J Med. 2020 Nov 26;383(22):2186-2187. doi: 10.1056/NEJMc2028904. N Engl J Med. 2020. PMID: 33252878 No abstract available.
-
The FEMME Trial: At Risk for Misinterpretation and "Fake News".Cardiovasc Intervent Radiol. 2021 May;44(5):673-674. doi: 10.1007/s00270-020-02755-4. Epub 2021 Jan 5. Cardiovasc Intervent Radiol. 2021. PMID: 33399926 No abstract available.
-
Excerpts from the World Medical Literature.J Obstet Gynaecol Can. 2021 Mar;43(3):290-293. doi: 10.1016/j.jogc.2020.12.010. J Obstet Gynaecol Can. 2021. PMID: 33640097 No abstract available.